Recombinant adeno-associated virus (rAAV) has been developed as a successful vector for both basic research and human gene therapy. However. neutralizing antibodies (NAbs) against AAV capsids can abolish AAV infectivity on target cells. reducing the transduction efficacy. https://www.fitnessgravesyardes.shop/product-category/left-heart-rate-grip/